Applications opened today for the 2019 Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.
In 2016, in celebration of the company’s 100 year anniversary, CSL established a flagship $25 million fellowship program to champion excellence in early stage translational research.
As well as paying tribute to CSL’s origins, the fellowships aim to foster a thriving medical research community by supporting the development of Australian science.
“Australia is home to CSL’s global hub for early research and translation medicine and we are committed to helping grow the quality and quantity of Australian research and our biotech ecosystem generally,” said Professor Andrew Cuthbertson AO, CSL Chief Scientific Officer and Director of Research & Development.
“These fellowships are long term, high value, and mid-career. I am confident that the recipients of the CSL Centenary Fellowships will go on to become some of Australia’s most eminent scientists and will lead the next generation of Australian scientific endeavour,” said Professor Cuthbertson.
There are now four active CSL Fellows working at the QIMR Berghofer Institute, the Queensland Brain Institute, the Peter MacCallum Cancer Centre and The Baker Heart and Diabetes Institute. Their research includes work on improving survival rates for patients with acute leukaemia, whether memories are stored in our DNA, liquid biopsies for cancer testing, and what really causes arteries to clog.
In 2019, we thank Professor Carola Vinuesa for her work as a member of the CSL Centenary Fellowships Selection Committee and welcome Professor Sharon Lewin, Director of the Doherty Institute as a new member on the independent selection committee, joining Professor Ashley Dunn, and Stephan Jane.
The winners of the 2019 CSL Centenary Fellowships will be announced on 11th October 2018 at the annual dinner of the Australian Academy of Health and Medical Sciences.
For more information, including application details, visit: www.cslfellowships.com.au
ABOUT CSL: CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 60 countries and employs nearly 20,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com.au
Media Contact
Christina Hickie
CSL Limited
Phone: +61 9389 3425/ 0429 609 762